{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:43:57Z","timestamp":1769600637430,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although inflammation is central to gallbladder cancer (GBC) development and proliferation, no study has systematically investigated circulating inflammatory proteins and patient survival. We aimed to examine whether the circulating levels of inflammatory proteins is associated with all-cause mortality among such patients. We recruited 134 patients with newly diagnosed with GBC from 1997 to 2001 in a population-based study in Shanghai and an independent set of 35 patients from 2012 to 2013 in Chile. Cox proportional hazards regression models adjusted for covariates were used to evaluate the hazard ratios (HRs) for death by serum levels of 49 inflammatory proteins (quartiles). Of 49 evaluable proteins, eight were significantly associated with overall survival. Seven were associated with a poorer survival, while the highest levels of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were associated with an increase in survival (HR\u2009=\u20090.26, 95% CI\u2009=\u20090.14, 0.47). No substantial difference in the magnitude of the association was observed between early- and late-stages of GBC. Of seven proteins, five were validated in the patients from Chile. Reducing inflammation and targeting pathways associated with increased survival might improve GBC outcomes. The potential for using a TRAIL-related anticancer drug for GBC treatment merits further investigation.<\/jats:p>","DOI":"10.1038\/s41598-018-23848-8","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T22:41:16Z","timestamp":1522363276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0136-651X","authenticated-orcid":false,"given":"Zhiwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy J.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Tang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Corbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma E.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Roa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Araya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann W.","family":"Hsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Hildesheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catterina","family":"Ferreccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth M.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligia A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-6204","authenticated-orcid":false,"given":"Jill","family":"Koshiol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"23848_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","volume":"51","author":"EC Lazcano-Ponce","year":"2001","unstructured":"Lazcano-Ponce, E. C. et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51, 349\u2013364 (2001).","journal-title":"CA Cancer J Clin"},{"key":"23848_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/annonc\/mdn533","volume":"20","author":"G Randi","year":"2009","unstructured":"Randi, G. et al. Epidemiology of biliary tract cancers: an update. Ann Oncol 20, 146\u2013159, https:\/\/doi.org\/10.1093\/annonc\/mdn533 (2009).","journal-title":"Ann Oncol"},{"key":"23848_CR3","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1002\/ijc.25421","volume":"127","author":"E Bertran","year":"2010","unstructured":"Bertran, E., Heise, K., Andia, M. E. & Ferreccio, C. Gallbladder cancer: incidence and survival in a high-risk area of Chile. Int J Cancer 127, 2446\u20132454, https:\/\/doi.org\/10.1002\/ijc.25421 (2010).","journal-title":"Int J Cancer"},{"key":"23848_CR4","doi-asserted-by":"crossref","unstructured":"Koshiol, J., Ferreccio, C., Devesa, S. S., Roa, J. C. & Fraumeni, J. F. J. Biliary Tract Cancer. Cancer Epidemiology and Prevention (2017).","DOI":"10.1093\/oso\/9780190238667.003.0034"},{"key":"23848_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1634\/theoncologist.2009-0302","volume":"15","author":"AX Zhu","year":"2010","unstructured":"Zhu, A. X., Hong, T. S., Hezel, A. F. & Kooby, D. A. Current management of gallbladder carcinoma. Oncologist 15, 168\u2013181, https:\/\/doi.org\/10.1634\/theoncologist.2009-0302 (2010).","journal-title":"Oncologist"},{"key":"23848_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1245\/s10434-006-9224-4","volume":"14","author":"RP Kiran","year":"2007","unstructured":"Kiran, R. P., Pokala, N. & Dudrick, S. J. Incidence pattern and survival for gallbladder cancer over three decades\u2013an analysis of 10301 patients. Ann Surg Oncol 14, 827\u2013832, https:\/\/doi.org\/10.1245\/s10434-006-9224-4 (2007).","journal-title":"Ann Surg Oncol"},{"key":"23848_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/00000658-200010000-00011","volume":"232","author":"Y Fong","year":"2000","unstructured":"Fong, Y., Jarnagin, W. & Blumgart, L. H. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 232, 557\u2013569 (2000).","journal-title":"Ann Surg"},{"key":"23848_CR8","doi-asserted-by":"publisher","first-page":"e0166361","DOI":"10.1371\/journal.pone.0166361","volume":"11","author":"C Chen","year":"2016","unstructured":"Chen, C. et al. Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage. PLoS One 11, e0166361, https:\/\/doi.org\/10.1371\/journal.pone.0166361 (2016).","journal-title":"PLoS One"},{"key":"23848_CR9","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s11605-012-1901-y","volume":"16","author":"LM Mazer","year":"2012","unstructured":"Mazer, L. M. et al. Tumor characteristics and survival analysis of incidental versus suspected gallbladder carcinoma. J Gastrointest Surg 16, 1311\u20131317, https:\/\/doi.org\/10.1007\/s11605-012-1901-y (2012).","journal-title":"J Gastrointest Surg"},{"key":"23848_CR10","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","volume":"21","author":"JF Rossi","year":"2015","unstructured":"Rossi, J. F., Lu, Z. Y., Jourdan, M. & Klein, B. Interleukin-6 as a therapeutic target. Clin Cancer Res 21, 1248\u20131257, https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2291 (2015).","journal-title":"Clin Cancer Res"},{"issue":"24","key":"23848_CR11","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1200\/JCO.2017.72.3569","volume":"35","author":"Xinwei Hua","year":"2017","unstructured":"Hua, X. et al. Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. J Clin Oncol, JCO2017723569, https:\/\/doi.org\/10.1200\/JCO.2017.72.3569 (2017).","journal-title":"Journal of Clinical Oncology"},{"key":"23848_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrclinonc.2012.137","volume":"9","author":"WK Chia","year":"2012","unstructured":"Chia, W. K., Ali, R. & Toh, H. C. Aspirin as adjuvant therapy for colorectal cancer\u2013reinterpreting paradigms. Nat Rev Clin Oncol 9, 561\u2013570, https:\/\/doi.org\/10.1038\/nrclinonc.2012.137 (2012).","journal-title":"Nat Rev Clin Oncol"},{"key":"23848_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.canlet.2013.08.034","volume":"345","author":"Y Li","year":"2014","unstructured":"Li, Y., Zhang, J. & Ma, H. Chronic inflammation and gallbladder cancer. Cancer Lett 345, 242\u2013248, https:\/\/doi.org\/10.1016\/j.canlet.2013.08.034 (2014).","journal-title":"Cancer Lett"},{"key":"23848_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cyto.2016.05.003","volume":"83","author":"J Koshiol","year":"2016","unstructured":"Koshiol, J. et al. Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies. Cytokine 83, 217\u2013225, https:\/\/doi.org\/10.1016\/j.cyto.2016.05.003 (2016).","journal-title":"Cytokine"},{"key":"23848_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.annepidem.2016.08.009","volume":"26","author":"AL Van Dyke","year":"2016","unstructured":"Van Dyke, A. L. et al. Lipopolysaccharide-pathway proteins are associated with gallbladder cancer among adults in Shanghai, China with mediation by systemic inflammation. Ann Epidemiol 26, 704\u2013709, https:\/\/doi.org\/10.1016\/j.annepidem.2016.08.009 (2016).","journal-title":"Ann Epidemiol"},{"key":"23848_CR16","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/ajg.2016.345","volume":"111","author":"S Ryu","year":"2016","unstructured":"Ryu, S. et al. Gallstones and the Risk of Gallbladder Cancer Mortality: A Cohort Study. Am J Gastroenterol 111, 1476\u20131487, https:\/\/doi.org\/10.1038\/ajg.2016.345 (2016).","journal-title":"Am J Gastroenterol"},{"key":"23848_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbcan.2016.03.004","volume":"1865","author":"JA Espinoza","year":"2016","unstructured":"Espinoza, J. A. et al. The inflammatory inception of gallbladder cancer. Biochim Biophys Acta 1865, 245\u2013254, https:\/\/doi.org\/10.1016\/j.bbcan.2016.03.004 (2016).","journal-title":"Biochim Biophys Acta"},{"key":"23848_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/aje\/kwt322","volume":"179","author":"L Nogueira","year":"2014","unstructured":"Nogueira, L. et al. Gallstones, cholecystectomy, and risk of digestive system cancers. Am J Epidemiol 179, 731\u2013739, https:\/\/doi.org\/10.1093\/aje\/kwt322 (2014).","journal-title":"Am J Epidemiol"},{"key":"23848_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s12094-015-1310-2","volume":"17","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y., Jiang, C., Li, J., Sun, J. & Qu, X. Prognostic significance of preoperative neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio in patients with gallbladder carcinoma. Clin Transl Oncol 17, 810\u2013818, https:\/\/doi.org\/10.1007\/s12094-015-1310-2 (2015).","journal-title":"Clin Transl Oncol"},{"key":"23848_CR20","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.21873\/anticanres.11053","volume":"36","author":"T Abe","year":"2016","unstructured":"Abe, T. et al. Preoperative Systemic Inflammation and Complications Affect Long-term Gallbladder Carcinoma Outcomes Following Surgery with Curative Intent. Anticancer Res 36, 4887\u20134894, https:\/\/doi.org\/10.21873\/anticanres.11053 (2016).","journal-title":"Anticancer Res"},{"key":"23848_CR21","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.3892\/mmr.2014.3143","volume":"11","author":"M Zhang","year":"2015","unstructured":"Zhang, M. et al. Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer. Mol Med Rep 11, 3539\u20133546, https:\/\/doi.org\/10.3892\/mmr.2014.3143 (2015).","journal-title":"Mol Med Rep"},{"key":"23848_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ijc.30134","volume":"139","author":"R Sudam Patil","year":"2016","unstructured":"Sudam Patil, R. et al. IL17 producing gammadeltaT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer 139, 869\u2013881, https:\/\/doi.org\/10.1002\/ijc.30134 (2016).","journal-title":"Int J Cancer"},{"key":"23848_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2313-2","volume":"16","author":"PP Bao","year":"2016","unstructured":"Bao, P. P. et al. Cancer incidence in urban Shanghai, 1973\u20132010: an updated trend and age-period-cohort effects. BMC Cancer 16, 284, https:\/\/doi.org\/10.1186\/s12885-016-2313-2 (2016).","journal-title":"BMC Cancer"},{"key":"23848_CR24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1158\/1055-9965.EPI-15-0199","volume":"24","author":"SJ Henley","year":"2015","unstructured":"Henley, S. J., Weir, H. K., Jim, M. A., Watson, M. & Richardson, L. C. Gallbladder Cancer Incidence and Mortality, United States 1999-2011. Cancer Epidemiol Biomarkers Prev 24, 1319\u20131326, https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0199 (2015).","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"23848_CR25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/sj.bjc.6604047","volume":"97","author":"AW Hsing","year":"2007","unstructured":"Hsing, A. W. et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 97, 1577\u20131582, https:\/\/doi.org\/10.1038\/sj.bjc.6604047 (2007).","journal-title":"Br J Cancer"},{"key":"23848_CR26","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2015.4559","volume":"313","author":"L Nogueira","year":"2015","unstructured":"Nogueira, L. et al. Association of aflatoxin with gallbladder cancer in Chile. JAMA 313, 2075\u20132077, https:\/\/doi.org\/10.1001\/jama.2015.4559 (2015).","journal-title":"JAMA"},{"key":"23848_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0021-9681(82)90058-3","volume":"35","author":"RW Makuch","year":"1982","unstructured":"Makuch, R. W. Adjusted survival curve estimation using covariates. J Chronic Dis 35, 437\u2013443 (1982).","journal-title":"J Chronic Dis"},{"key":"23848_CR28","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1001\/jama.286.12.1494","volume":"286","author":"WA Ghali","year":"2001","unstructured":"Ghali, W. A. et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 286, 1494\u20131497 (2001).","journal-title":"JAMA"},{"key":"23848_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0016-5085(85)90324-5","volume":"89","author":"JC Sheu","year":"1985","unstructured":"Sheu, J. C. et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 89, 259\u2013266 (1985).","journal-title":"Gastroenterology"},{"key":"23848_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/hep.1840160122","volume":"16","author":"L Barbara","year":"1992","unstructured":"Barbara, L. et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 16, 132\u2013137 (1992).","journal-title":"Hepatology"},{"key":"23848_CR31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan, D. C. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39, 534\u2013540, https:\/\/doi.org\/10.1016\/j.ctrv.2012.08.003 (2013).","journal-title":"Cancer Treat Rev"},{"key":"23848_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.semcancer.2004.06.006","volume":"14","author":"M Philip","year":"2004","unstructured":"Philip, M., Rowley, D. A. & Schreiber, H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14, 433\u2013439, https:\/\/doi.org\/10.1016\/j.semcancer.2004.06.006 (2004).","journal-title":"Semin Cancer Biol"},{"key":"23848_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-213","volume":"11","author":"PA Cassier","year":"2011","unstructured":"Cassier, P. A. et al. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer 11, 213, https:\/\/doi.org\/10.1186\/1471-2407-11-213 (2011).","journal-title":"BMC Cancer"},{"key":"23848_CR34","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.18632\/oncotarget.1426","volume":"4","author":"PJ Sarvaiya","year":"2013","unstructured":"Sarvaiya, P. J., Guo, D., Ulasov, I., Gabikian, P. & Lesniak, M. S. Chemokines in tumor progression and metastasis. Oncotarget 4, 2171\u20132185, https:\/\/doi.org\/10.18632\/oncotarget.1426 (2013).","journal-title":"Oncotarget"},{"key":"23848_CR35","first-page":"221","volume":"3","author":"H Loetscher","year":"1991","unstructured":"Loetscher, H., Steinmetz, M. & Lesslauer, W. Tumor necrosis factor: receptors and inhibitors. Cancer Cells 3, 221\u2013226 (1991).","journal-title":"Cancer Cells"},{"key":"23848_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2903","volume":"13","author":"Y Kodera","year":"2011","unstructured":"Kodera, Y. et al. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 13, R66, https:\/\/doi.org\/10.1186\/bcr2903 (2011).","journal-title":"Breast Cancer Res"},{"key":"23848_CR37","first-page":"616","volume":"5","author":"ML Varney","year":"2015","unstructured":"Varney, M. L. & Singh, R. K. VEGF-C-VEGFR3\/Flt4 axis regulates mammary tumor growth and metastasis in an autocrine manner. Am J Cancer Res 5, 616\u2013628 (2015).","journal-title":"Am J Cancer Res"},{"key":"23848_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","volume":"1","author":"ER Rayburn","year":"2009","unstructured":"Rayburn, E. R., Ezell, S. J. & Zhang, R. Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol 1, 29\u201343, https:\/\/doi.org\/10.4255\/mcpharmacol.09.05 (2009).","journal-title":"Mol Cell Pharmacol"},{"key":"23848_CR39","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/bjc.2014.90","volume":"110","author":"CS Roxburgh","year":"2014","unstructured":"Roxburgh, C. S. & McMillan, D. C. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 110, 1409\u20131412, https:\/\/doi.org\/10.1038\/bjc.2014.90 (2014).","journal-title":"Br J Cancer"},{"key":"23848_CR40","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","volume":"15","author":"S Shinriki","year":"2009","unstructured":"Shinriki, S. et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 15, 5426\u20135434, https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0287 (2009).","journal-title":"Clin Cancer Res"},{"key":"23848_CR41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo, Y., Xu, F., Lu, T., Duan, Z. & Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38, 904\u2013910, https:\/\/doi.org\/10.1016\/j.ctrv.2012.04.007 (2012).","journal-title":"Cancer Treat Rev"},{"key":"23848_CR42","first-page":"762","volume":"9","author":"JM Lancaster","year":"2003","unstructured":"Lancaster, J. M. et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 9, 762\u2013766 (2003).","journal-title":"Clin Cancer Res"},{"key":"23848_CR43","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/cncr.25504","volume":"117","author":"M Anees","year":"2011","unstructured":"Anees, M. et al. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 117, 1172\u20131182, https:\/\/doi.org\/10.1002\/cncr.25504 (2011).","journal-title":"Cancer"},{"key":"23848_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcdb.2015.01.012","volume":"39","author":"SP Cullen","year":"2015","unstructured":"Cullen, S. P. & Martin, S. J. Fas and TRAIL \u2018death receptors\u2019 as initiators of inflammation: Implications for cancer. Semin Cell Dev Biol 39, 26\u201334, https:\/\/doi.org\/10.1016\/j.semcdb.2015.01.012 (2015).","journal-title":"Semin Cell Dev Biol"},{"key":"23848_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1006\/cimm.2001.1896","volume":"214","author":"K Takeda","year":"2001","unstructured":"Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol 214, 194\u2013200, https:\/\/doi.org\/10.1006\/cimm.2001.1896 (2001).","journal-title":"Cell Immunol"},{"key":"23848_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1172\/JCI33061","volume":"118","author":"A Grosse-Wilde","year":"2008","unstructured":"Grosse-Wilde, A. et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118, 100\u2013110, https:\/\/doi.org\/10.1172\/JCI33061 (2008).","journal-title":"J Clin Invest"},{"key":"23848_CR47","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/onc.2012.164","volume":"32","author":"LY Dimberg","year":"2013","unstructured":"Dimberg, L. Y. et al. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32, 1341\u20131350, https:\/\/doi.org\/10.1038\/onc.2012.164 (2013).","journal-title":"Oncogene"},{"key":"23848_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cyto.2017.02.016","volume":"95","author":"WY Huang","year":"2017","unstructured":"Huang, W. Y. et al. Impact of freeze-thaw cycles on circulating inflammation marker measurements. Cytokine 95, 113\u2013117, https:\/\/doi.org\/10.1016\/j.cyto.2017.02.016 (2017).","journal-title":"Cytokine"}],"updated-by":[{"DOI":"10.1038\/s41598-020-59761-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23848-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T04:03:34Z","timestamp":1671595414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23848-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23848"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23848-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-020-59761-2","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"assertion":[{"value":"24 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5671"}}